However, the influence of ATG5 genotypes on cancer prognosis remains largely unexplored, and only one study suggested that heterozygous loss of ATG5 was associated with resistance to anticancer treatment and metastasis risk in melanoma patients [17]. This evidence concerns the gene ATG5 and cancer.